Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.

Slides:

Advertisements

Similar presentations

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.

Advertisements

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Management of severe anemia secondary to menorrhagia in a Jehovah's Witness: a case report and treatment algorithm Griselda Gutierrez, MD, FACOG, Joy.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation.

Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST) Kirsten E. Fleischmann,

Downstream coronary effects of drug-eluting stents

Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Colloquium on Therapy of Right Heart Failure

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

The Epidemic of the 20th Century: Coronary Heart Disease

Force- and relaxation-frequency relations in patients with diastolic heart failure Takashi Yamanaka, MD, Katsuya Onishi, MD, FACC, Masaki Tanabe, MD,

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics Cheryl Bushnell,

CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results.

Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population Richard K. Cheng, MD, MS,

Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study.

Impact of weight reduction on pericardial adipose tissue and cardiac structure in patients with atrial fibrillation Hany S. Abed, BPharm, MBBS, PhD,

Variation among hospitals in selection of higher-cost, “higher-tech,” implantable cardioverter-defibrillators: Data from the National Cardiovascular Data.

NT–probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non–ST-elevation acute coronary syndromes José.

Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: An analysis from the Blue Cross Blue Shield of Michigan.

Evaluating the safety and efficacy of sodium-restricted/Dietary Approaches to Stop Hypertension diet after acute decompensated heart failure hospitalization:

Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation Anh L. Bui, MD, Maria.

Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice Manesh R.

Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: An open-label, blinded end point, randomized.

National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance Judith.

Roy D. Ayalon, MD, Frederick Friedman, MD

Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective.

Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The.

Amay Parikh, MD, MBA, MS, Kunal Gupta, MD, MBA, Alan C

An Unusual Cause of Leg Ulcerations

Maureen M. Okam, MD, MPH, Todd A. Koch, Minh-Ha Tran, DO

Relationship between perioperative N-terminal pro-brain natriuretic peptide and maximum inotropic score in children after cardiac surgery Yanqin Cui,

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Association of Self-reported Physical Activity With Laboratory Markers of Nutrition and Inflammation: The Comprehensive Dialysis Study Shuchi Anand,

The Heart Failure Team Heart Failure Care Map First 24 hours.

G. Michael Felker et al. JCHF 2014;2:

The Epidemic of the 20th Century: Coronary Heart Disease

Osteoporotic Fractures and Heart Failure in the Community

Assessment of FIBROSpect II to Detect Hepatic Fibrosis in Chronic Hepatitis C Patients Atif Zaman, MD, MPH, Hugo R. Rosen, MD, Ken Ingram, PA-C, Christopher.

Loop Diuretics for Heart Failure-associated Hyponatremia

Treatment of hepatitis C

Use of Serum c-Peptide Level to Simplify Diabetes Treatment Regimens in Older Adults Medha N. Munshi, MD, Mellody Hayes, BA, Adrianne Sternthal, Darlene.

Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: A randomized controlled.

Transdermal Fentanyl for Chronic Pain in AIDS

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea George A. Alba, MD, Quynh A. Truong,

Hemoglobin Level and Transfusions in Patients on Maintenance Dialysis: Where the Rubber Meets the Road Eduardo Lacson, MD, MPH, Franklin Maddux, MD

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

On Statin Treatment to Prevent Sepsis in Dialysis Patients

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

The Reply The American Journal of Medicine

Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Diagnosing pancreatic malignancy in the setting of chronic pancreatitis: is there room for improvement? James J. Farrell, MD Gastrointestinal Endoscopy

John A. Batsis, MD, Francisco Lopez-Jimenez, MD, MSc, Maria L

Niv Ad, MD, Lawrence M. Wei, MD

Is endoluminal vacuum therapy “sponge worthy”?

Plasma Lactescence in Acute Pancreatitis

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Kidney Failure Treatment: The Freedom to Choose

Primary Care Management of Skin Abscesses Guided by Ultrasound

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

Tofacitinib therapy for children with severe alopecia areata

Emily G. McDonald, MD, MSc, Ramy R. Saleh, MD, Todd C. Lee, MD, MPH

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Presentation transcript:

Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study Anju Bhardwaj, MD, Shafiq U. Rehman, MD, Asim A. Mohammed, MD, Hanna K. Gaggin, MD, MPH, Linda Barajas, RN, Justine Barajas, Stephanie A. Moore, MD, Dorothy Sullivan, NP, James L. Januzzi, MD American Heart Journal Volume 164, Issue 5, Pages 793-799.e1 (November 2012) DOI: 10.1016/j.ahj.2012.08.015 Copyright © 2012 Mosby, Inc. Terms and Conditions

Figure 1 Quality of life scores at each visit for each treatment group. At baseline, overall Minnesota Living with Heart Failure Questionnaire scores were comparable between SOC and NT-proBNP guided arms. While both groups showed improved quality of life, overall scores improved more in the NT-proBNP study arm. American Heart Journal 2012 164, 793-799.e1DOI: (10.1016/j.ahj.2012.08.015) Copyright © 2012 Mosby, Inc. Terms and Conditions

Figure 2 Correlation between relative change in Minnesota Living with Heart failure questionnaire score and relative change in NT-proBNP concentrations. A significant correlation exists after study procedures; a cubic fit line is displayed. American Heart Journal 2012 164, 793-799.e1DOI: (10.1016/j.ahj.2012.08.015) Copyright © 2012 Mosby, Inc. Terms and Conditions

Figure 3 Event rates as a function of Minnesota Living with Heart Failure Questionnaire tertile. Those with the least improvement in their quality of life scores had the highest event rates. American Heart Journal 2012 164, 793-799.e1DOI: (10.1016/j.ahj.2012.08.015) Copyright © 2012 Mosby, Inc. Terms and Conditions

Supplemental Figure 1 Improvement in quality of life compared to the change in NT-proBNP levels. The most remarkable improvement was observed in patients with most significant drop in NT-proBNP values, intermediate in patient with no change in NT-proBNP, and least in patients who had a rise in NT-proBNP levels American Heart Journal 2012 164, 793-799.e1DOI: (10.1016/j.ahj.2012.08.015) Copyright © 2012 Mosby, Inc. Terms and Conditions